Stien De Coninck, Renate De Smedt, Beatrice Lintermans, Lindy Reunes, Hansen J Kosasih, Alexandra Reekmans, Lauren M Brown, Nadine Van Roy, Bruno Palhais, Juliette Roels, Malaika Van der Linden, Jo Van Dorpe, Panagiotis Ntziachristos, Frederik W Van Delft, Marc R Mansour, Tim Pieters, Tim Lammens, Barbara De Moerloose, Charles E De Bock, Steven Goossens, Pieter Van Vlierberghe
T cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL) are rare aggressive hematological malignancies. Current treatment consists of intensive chemotherapy, leading to 80% overall survival but are associated with severe toxic side effects. Furthermore, 10-20% of patients still die from relapsed or refractory disease providing a strong rationale for more specific, targeted therapeutic strategies with less toxicities. Here, we report a novel MYH9::PDGFRB fusion in a T-LBL patient and demonstrate that this fusion product is constitutively active and sufficient to drive oncogenic transformation in vitro and in vivo...
November 9, 2023: Haematologica